CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq’s MarketSite and Announces Presentation at World Immunot...
September 24 2019 - 10:20AM
INmune Bio, Inc. (NASDAQ: INMB), an immunology company
focused on developing treatments that harness the patient’s innate
immune system to fight disease, today announced that RJ Tesi, M.D.,
Co-Founder and CEO will be featured in an interview with multimedia
financial reporter, Jason Lin discussing the company’s
accomplishments. The interview can be found by clicking here.
“Nasdaq’s MarketSite is a premiere platform for INmune Bio to
share our story with investors and to discuss recent developments
in our programs for cancer, Alzheimer’s disease and nonalcoholic
steatohepatitis (NASH) liver disease,” said Dr. Tesi. “We hope to
continue reaching new milestones in the development of therapies
that target the innate immune system.”
INmune Bio has four drug development programs: two that are
designed to treat cancer, INKmune™ and INB03 — with recently
reported positive preliminary data from the Phase 1 trial in
patients with advanced cancer; XPro1595 for the treatment of
neuroinflammation and Alzheimer’s disease; and NeuLiv™ for the
treatment of NASH.
Additionally, CJ Barnum, Ph.D., Director of Neuroscience, will
present on “Approaching Alzheimer’s disease as an immunological
disease: role of biomarkers” at the World Immunotherapy Congress on
Oct. 16 in Switzerland. About INmune Bio,
Inc.INmune Bio, Inc. is a publicly traded (NASDAQ:
INMB), clinical-stage biotechnology company focused on developing
treatments that target the innate immune system to fight disease.
INmune Bio has two product platforms. The DN-TNF product
platform utilizes dominant-negative technology to selectively
neutralize soluble TNF, a key driver of innate immune dysfunction
and mechanistic target of many diseases. DN-TNF is currently being
developed for cancer (INB03), Alzheimer’s (XPro595), and NASH
(NeuLiv). The Innate Immune Priming Platform includes INKmune aimed
at priming the patient’s NK cells to eliminate minimal residual
disease in patients with cancer. INmune Bio’s product
platforms utilize a precision medicine approach for the treatment
of a wide variety of hematologic malignancies, solid tumors and
chronic inflammation. To learn more, please visit
www.inmunebio.com.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations but are subject to a number of risks
and uncertainties. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. INBO3, XPro1595, INKmune and NeuLiv are still in
clinical trials and have not been approved and there cannot be any
assurance that they will be approved. The factors that could cause
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K for the year ended December
31, 2018, the Company’s Quarterly Reports on Form 10-Q and the
Company’s Current Reports on Form 8-K. The Company assumes no
obligation to update any forward-looking statements in order to
reflect any event or circumstance that may arise after the date of
this release.
INmune Bio Contact: David Moss, CFO(858)
964-3720DMoss@INmuneBio.com
Media Contact: Antenna GroupHolly Dugan(201)
465-8019INmuneBio@AntennaGroup.com
David SchullRusso Partners(212)
845-4271David.Schull@russopartnersllc.com
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2024 to May 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From May 2023 to May 2024